Meet Our Analysts

Ed Arce
Managing Director, Senior Healthcare Analyst

  • Ed Arce is a Managing Director of Equity Research specializing in the biopharmaceutical and specialty pharmaceutical sectors.
  • Mr. Arce’s focus is in investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies.
  • Mr. Arce has been engaged in institutionally-focused healthcare research since 2005. Prior to HCW, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
  • Mr. Arce holds a Master of Science in Finance (MSF) degree from Boston College, as well as an MBA and a B.S. in Civil Engineering, both from Florida International University (FIU). Mr. Arce is also a Board-licensed Professional Engineer (P.E.), and a Level III CFA candidate.

Yi Chen, Ph.D., CFA
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.

  • Dr. Yi Chen is a Managing Director of Equity Research with expertise in the biotechnology and pharmaceutical sectors.
  • Dr. Chen’s focus is on investment opportunities in the U.S. healthcare sector as well as emerging growth opportunities in the China healthcare sector. Prior to joining H.C. Wainwright, Dr. Chen held positions as an Associate Director in healthcare equity research at both Aegis Capital Corp. and Morgan Joseph TriArtisan, LLC. He also worked as a trading associate at Zhang Capital Management, a New York-based buy-side fund. Dr. Chen’s research career focused on protein signaling domains utilizing an RNA interference approach during while he was a research associate at the City University of New York. He has published articles in leading peer-reviewed journals, presented research at various scientific conferences, and has been an instructor in biology laboratory courses at Hunter College in New York City.
  • Dr. Chen obtained his Ph.D. in biochemistry from the City University of New York in February 2007, and B.S. in Biophysics from Fudan University in July 1999. He is a Chartered Financial Analyst (CFA) charter holder.

Corey Davis, Ph.D.
Managing Director, Senior Heathcare Analyst

  • Corey Davis is a Managing Director focused on specialty pharmaceuticals research.
  • Mr. Davis has covered the Specialty Pharmaceuticals sector for 19 years. Prior to joining H.C. Wainwright, Mr. Davis was at Canaccord Genuity for two years and prior to that was at Jefferies for four years. Mr. Davis began his career in 1997 at Hambrecht & Quist and remained as the firm became JP Morgan through acquisitions.
  • Mr. Davis graduated Magna Cum Laude from Middlebury in 1991 and received his Ph.D. in molecular biology from Princeton in 1997.
  • Mr. Davis has been named to the Institutional Investor All-America Team four times (2002-2006). Mr. Davis won the Thomson Reuters “#1 Stock Picker” award in Pharmaceuticals in 2014, and was Business Insider’s overall #1 Stock Picker among all sectors on Wall Street for 2013. Mr. Davis is frequently quoted in print media and appears regularly on TV programs such as CNBC, Bloomberg TV, and BNN.

Amit Dayal
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.

  • Amit Dayal is a Managing Director at HCW where he is focused on research for small cap growth companies listed in the U.S. Prior to joining HCW, Mr. Dayal was advising and investing in early stage technology startups. Prior to that, Mr. Dayal was a Senior Research Analyst at Rodman & Renshaw for seven years  where he focused on covering small and mid cap companies in verticals including TMT (Technology Media Telecom), Clean Tech, Industrials and Consumer. Mr. Dayal’s research coverage has included companies in emerging markets. His research emphasis is on underfollowed and growth oriented companies. Before joining Rodman & Renshaw, Mr. Dayal founded and later sold his own web services company that was operational in India and Nepal.
  • Mr. Dayal holds an MBA from Babson College, an M.Com from University of Delhi and a B.Com (Hons) from University of Delhi.

Shaunak K. Deepak
Managing Director, Senior Healthcare Analyst

  • Shaunak Deepak is a Managing Director focused on healthcare research.
  • Prior to joining HCW, Mr. Deepak was an Equity Analyst at Jefferies. Prior to Jefferies, Mr. Deepak covered the biotechnology sector as an Associate Analyst at Piper Jaffray, Rodman & Renshaw and Stifel Nicolaus.
  • Mr. Deepak received his AB degree from Harvard University.

Kevin Dede, CFA
Managing Director, Senior Technology Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.

  • Mr. Dede is a Managing Director and Equity Research Analyst at H.C. Wainwright. He has over 20 years of experience preparing institutional focused research covering several industries including telecommunications food chain, heavy industry, retail, financial services, and almost all realms of technology.  Mr. Dede began his career at Prudential Securities in 1992, and has subsequently worked at other sell-side investment banks including Montgomery Securities, Merriman Curhan & Ford, and most recently, Auriga LLC. Mr. Dede has been cited as a technology expert by Barrons, Bloomberg television/radio, and FOX News among other financial reporting agencies.
  • Mr. Dede has an MBA and an Engineering Degree from the U.S. Merchant Marine Academy.

Andrew Fein
Managing Director, Senior Healthcare Analyst

  • Andrew Fein is a Managing Director focused on healthcare research at HCW. Mr. Fein has more than a dozen years of biotechnology equity research experience. Previously, Mr. Fein headed the healthcare research effort at Chardan Capital Markets. Prior to working at Chardan, Mr. Fein held Managing Director/Senior Biotechnology Analyst positions at Jefferies, Piper Jaffray and Collins Stewart from 2005 to 2010. Mr. Fein, began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. He has received honorable mention numerous times from the Institutional Investor All-America research poll
  • Andrew received his Bachelor of Arts degree from Yale University.

Heiko Ihle, CFA
Managing Director, Senior Metals & Mining Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.

  • Heiko Ihle covers companies in the Metals & Mining industry.  Prior to joining H.C. Wainwright, Mr. Ihle spent 2.5 years at Euro Pacific Capital as a Senior Research Analyst, where he was also focused on the Mining industry. Before this, he spent over 6 years working on Equity Research with Gabelli & Company in Rye, NY with a focus on the Industrials and E&C industries. Prior to his time at Gabelli, he completed summer internships with Deutsche Bank on the foreign exchange trading desk in New York, NY and in fixed income sales in Frankfurt, Germany.
  • A native of Germany, Mr. Ihle received his Bachelor in Finance and Management from the University of Illinois at Chicago in 2004 and his MBA from the University of Miami in 2006. He has been a CFA Charterholder since 2010 and is currently a member of the CFA Institute and the Stamford CFA Society.

Joseph Pantginis, Ph.D.
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co. 

  • Dr. Joseph Pantginis, Ph.D., is a Managing Director at Rodman & Renshaw, a unit of H.C. Wainwright, focused on healthcare research.
  • Dr. Pantginis has over 15 years of experience in healthcare equity research. Prior to joining Rodman & Renshaw, Dr. Pantginis was most recently Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Prior positions included senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.
  • Dr. Pantginis earned a Ph.D. and M.S. in molecular genetics from the Albert Einstein College of Medicine as well as an M.B.A. from Pace University.

Swayampakula Ramakanth, Ph.D.
Managing Director, Senior Healthcare Analyst

  • Dr. Swayampakula Ramakanth joined HCW in June, 2014 to focus on healthcare research.
  • Dr. Ramakanth’s expertise consists of companies in the oncology, infectious diseases, metabolic disorders and animal health sectors. Dr. Ramakanth has over 10 years of experience as a life sciences equity analyst and 7 years of biotechnology industry experience. He has covered biotechnology and large cap pharmaceutical sectors.
  • Prior to joining H.C. Wainwright in June 2014, Dr. Ramakanth was a Junior Analyst at Jefferies and Merrill Lynch covering large cap pharmaceuticals, and at First Albany and Rodman & Renshaw covering biotechnology companies. Dr. Ramakanth previously conducted bench research at Regeneron Pharmaceuticals, Inc. and directed a preclinical drug development group.
  • Dr. Ramakanth earned his doctorate in Pharmacology/ Toxicology by characterizing a novel gene for a drug metabolizing enzyme.  His expertise includes drug metabolism, molecular biology and pre-clinical drug development. Dr. Ramakanth has presented at various regional and international conferences and published in peer-reviewed journals.  Dr. Ramakanth has a Ph.D. in Pharmacology/Toxicology from the University of Utah, a MBA from Rutgers University, M.S. in Pharmaceutics from Auburn University, and B. Pharm (Hons.) from BITS, India.  He held a post-doctoral fellowship at the University of Texas MD Anderson Cancer Center.

Raghuram Selvaraju, Ph.D.
Managing Director, Senior Healthcare Analyst
Rodman & Renshaw, a unit of H.C. Wainwright & Co.

  • Raghuram Selvaraju Ph.D., is a Managing Director at Rodman & Renshaw a unit of H.C. Wainwright focused on healthcare research.
  • Dr. Selvaraju possesses over a decade's worth of experience in healthcare equity research, and has been ranked by StarMine for earnings accuracy as well as The Wall Street Journal's "Best On The Street" survey for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV to comment on drug development trends, healthcare reform policy, and pharma and biotech M&A.
  • Prior to joining Rodman & Renshaw, Dr. Selvaraju held senior research positions at MLV & Co., Aegis Capital, Hapoalim Securities USA and Rodman & Renshaw LLC.
  • Dr. Selvaraju earned a Ph.D. in molecular neuroscience and cellular immunology as well as an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University.

Carol Werther
Managing Director, Senior Healthcare Analyst

  • Carol Werther has over 20 years’ experience following the biotechnology/pharmaceutical sectors both as a sell side and buy side analyst. Prior to joining HCW, Ms. Werther was a Vice President at Burns McClellan providing investor relations services to private and public biotechnology companies. Previously, Ms. Werther held sell-side positions, which included: Managing Director/Senior Biotechnology at CRT Capital Group, Summer Street Research Partners, Think Equity, LLC and Adams Harkness & Hill, Research Division. She also served as a Biotechnology Consultant providing biotechnology company analysis and recommendations to Winslow Management Co., Apollo Medical Partners and RX Capital, LLC. Ms. Werther also served as Co-Manager of the INVESCO Trust Company healthcare portfolio and Manager of Rothschild Asset Management Biotechnology Investment Trust. She began her career at first at Lehman Brothers Holdings Inc., Research Division and then at Cowen and Company, LLC, Research Division.
  • Ms. Werther has been recognized in the Wall Street Journal’s Best on the Street Survey in 2000 and 2001.
  • Ms. Werther earned her MBA in Finance at New York University‘s Stern School of Business. In addition, she has a M.S. and B.S. in Nutrition Sciences from The University of Alabama in Birmingham and Cornell University, respectively.